FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2106804959> ?p ?o ?g. }

• W2106804959 abstract "Few overlapping toxicities and oral formulations make capecitabine plus oral vinorelbine an attractive new combination for treating patients with breast cancer. An all-oral regimen minimizes inconvenience for the patient and saves medical resources.To determine the recommended dose for this all-oral combination, we conducted a phase I study in 21 patients with metastatic breast cancer after failure of previous chemotherapy with anthracylines and/or taxanes for advanced disease. Capecitabine 1000 mg/m2 twice daily was given on days 2-7 and 9-14. Vinorelbine was administered at escalating doses of 40-80 mg/m2 on days 1 and 8 every 3 weeks. Dose escalation of vinorelbine was performed in cohorts of 3 patients, but the dose of vinorelbine could also be increased to the next level in the same patient after 3 cycles if there were no dose-limiting toxicities. In total, 173 cycles were administered (median, 8 cycles; range 1-21+ cycles).Treatment was well tolerated: there were no grade 4 toxicities, and the only grade 3 toxicities in > 1 cycle were hand-foot syndrome and neutropenia (2% of cycles each). The maximum tolerated dose could not be determined using predefined criteria. However, in this heavily pretreated patient population, intrapatient vinorelbine dose escalation > 60 mg/m2 was rarely achieved. Thus, we considered vinorelbine 60 mg/m2 to offer the best dose level-toxicity ratio. At this dose, grade 3 toxicities occurred in only 7% of the 58 cycles administered. Among 19 evaluable patients, 7 exhibited response or stable disease lasting > 6 months, giving a clinical benefit rate of 37%. Duration of response in the 2 responding patients was 5 months and > 16 months.The all-oral combination of capecitabine/vinorelbine is well tolerated and active in heavily pretreated patients. Oral vinorelbine 60 mg/m2 is recommended in combination with capecitabine 1000 mg/m2 twice daily for further evaluation." @default.
• W2106804959 created "2016-06-24" @default.
• W2106804959 creator A5040699734 @default.
• W2106804959 creator A5046452137 @default.
• W2106804959 creator A5071569694 @default.
• W2106804959 creator A5087922846 @default.
• W2106804959 creator A5090618504 @default.
• W2106804959 date "2006-12-01" @default.
• W2106804959 modified "2023-09-23" @default.
• W2106804959 title "A Phase I Study of an All-Oral Combination of Vinorelbine/Capecitabine in Patients with Metastatic Breast Cancer Previously Treated with Anthracyclines and/or Taxanes" @default.
• W2106804959 cites W1755746957 @default.
• W2106804959 cites W1843618725 @default.
• W2106804959 cites W1905936368 @default.
• W2106804959 cites W1939003096 @default.
• W2106804959 cites W1946638503 @default.
• W2106804959 cites W1966574632 @default.
• W2106804959 cites W1999691599 @default.
• W2106804959 cites W2025504439 @default.
• W2106804959 cites W2028353414 @default.
• W2106804959 cites W2028697269 @default.
• W2106804959 cites W2039310969 @default.
• W2106804959 cites W2040527029 @default.
• W2106804959 cites W2044970916 @default.
• W2106804959 cites W2083292321 @default.
• W2106804959 cites W2099658604 @default.
• W2106804959 cites W2108729453 @default.
• W2106804959 cites W2115931762 @default.
• W2106804959 cites W2123732467 @default.
• W2106804959 cites W2131770017 @default.
• W2106804959 cites W2132723220 @default.
• W2106804959 cites W2135378470 @default.
• W2106804959 cites W2139248078 @default.
• W2106804959 cites W2139582914 @default.
• W2106804959 cites W2143399650 @default.
• W2106804959 cites W2146478870 @default.
• W2106804959 cites W2158652816 @default.
• W2106804959 cites W2159356788 @default.
• W2106804959 cites W2212225357 @default.
• W2106804959 cites W2221085913 @default.
• W2106804959 cites W2293688022 @default.
• W2106804959 cites W2416933833 @default.
• W2106804959 doi "https://doi.org/10.3816/cbc.2006.n.057" @default.
• W2106804959 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17239265" @default.
• W2106804959 hasPublicationYear "2006" @default.
• W2106804959 type Work @default.
• W2106804959 sameAs 2106804959 @default.
• W2106804959 citedByCount "17" @default.
• W2106804959 countsByYear W21068049592012 @default.
• W2106804959 countsByYear W21068049592013 @default.
• W2106804959 countsByYear W21068049592017 @default.
• W2106804959 crossrefType "journal-article" @default.
• W2106804959 hasAuthorship W2106804959A5040699734 @default.
• W2106804959 hasAuthorship W2106804959A5046452137 @default.
• W2106804959 hasAuthorship W2106804959A5071569694 @default.
• W2106804959 hasAuthorship W2106804959A5087922846 @default.
• W2106804959 hasAuthorship W2106804959A5090618504 @default.
• W2106804959 hasConcept C121608353 @default.
• W2106804959 hasConcept C126322002 @default.
• W2106804959 hasConcept C143998085 @default.
• W2106804959 hasConcept C2775930923 @default.
• W2106804959 hasConcept C2776694085 @default.
• W2106804959 hasConcept C2777063308 @default.
• W2106804959 hasConcept C2777511904 @default.
• W2106804959 hasConcept C2777909004 @default.
• W2106804959 hasConcept C2778239845 @default.
• W2106804959 hasConcept C2780350996 @default.
• W2106804959 hasConcept C2781413609 @default.
• W2106804959 hasConcept C2908647359 @default.
• W2106804959 hasConcept C526805850 @default.
• W2106804959 hasConcept C530470458 @default.
• W2106804959 hasConcept C71924100 @default.
• W2106804959 hasConcept C99454951 @default.
• W2106804959 hasConceptScore W2106804959C121608353 @default.
• W2106804959 hasConceptScore W2106804959C126322002 @default.
• W2106804959 hasConceptScore W2106804959C143998085 @default.
• W2106804959 hasConceptScore W2106804959C2775930923 @default.
• W2106804959 hasConceptScore W2106804959C2776694085 @default.
• W2106804959 hasConceptScore W2106804959C2777063308 @default.
• W2106804959 hasConceptScore W2106804959C2777511904 @default.
• W2106804959 hasConceptScore W2106804959C2777909004 @default.
• W2106804959 hasConceptScore W2106804959C2778239845 @default.
• W2106804959 hasConceptScore W2106804959C2780350996 @default.
• W2106804959 hasConceptScore W2106804959C2781413609 @default.
• W2106804959 hasConceptScore W2106804959C2908647359 @default.
• W2106804959 hasConceptScore W2106804959C526805850 @default.
• W2106804959 hasConceptScore W2106804959C530470458 @default.
• W2106804959 hasConceptScore W2106804959C71924100 @default.
• W2106804959 hasConceptScore W2106804959C99454951 @default.
• W2106804959 hasLocation W21068049591 @default.
• W2106804959 hasLocation W21068049592 @default.
• W2106804959 hasOpenAccess W2106804959 @default.
• W2106804959 hasPrimaryLocation W21068049591 @default.
• W2106804959 hasRelatedWork W1985608906 @default.
• W2106804959 hasRelatedWork W2025504439 @default.
• W2106804959 hasRelatedWork W2056528636 @default.
• W2106804959 hasRelatedWork W2068339772 @default.
• W2106804959 hasRelatedWork W2079713072 @default.
• W2106804959 hasRelatedWork W2142770096 @default.
• W2106804959 hasRelatedWork W2550863097 @default.
• W2106804959 hasRelatedWork W3032128730 @default.

• next